ImmunityBio (IBRX) expects Q1 net product revenue of $44.2 million, a 168% year-over-year surge driven by ANKTIVA momentum. The immunotherapy is now authorized in 34 countries following a 700% revenue jump in 2025. Despite this strong guidance, IBRX stock edged 0.1% lower in pre-market trading on Thursday.